The Ad-CEA+N-803+OX40+4-1BB combination also inhibited tumor growth compared with control (p<0.0001); however, it was not different to that observed with OX40+4-1BB treatment (p=0.6625), indicating that most of the therapeutic activity may be due to the costimulatory molecule agonists in this combination. The gene discussed is TNFRSF4; the disease is neoplasm.